Yayınlar

Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Aslan AF, Bayram A, Mazicioglu M, Kalin Unuvar G, Yuce ZT, Aydin G, Kaya RK, Ates I, Kara A, Ozdarendeli A. Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines (Basel). 2024 Jan 29;12(2):140.

Ozdarendeli, A. (2023). Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development. Diagnostics, 13(16), 2708.

Ozdarendeli, A., Sezer, Z., Pavel, S. T. I., Inal, A., Yetiskin, H., Kaplan, B., Uygut MA... & Kara, A. (2023). Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials. Vaccine, 41(2), 380-390.

Ates, I., Batirel, A., Aydin, M., Karadag, F. Y., Erden, A., Kucuksahin, O., ….Ozdarendeli A….. & Kara, A. (2023). Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study. Vaccines, 11(7), 1234.

Mamedov, T., Yuksel, D., Gurbuzaslan, I., Ilgin, M., Gulec, B., Mammadova, G., ... & Hasanova, G. (2023). Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants. Frontiers in Plant Science, 14.

Omma, A., Batirel, A., Aydin, M., Yilmaz Karadag, F., Erden, A., Kucuksahin, O., .. Ozdarendeli, A.,. & Ates, I. (2022). Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial. Human Vaccines & Immunotherapeutics, 18(6), 2122503.

Tanriover, M. D., Aydin, O. A., Guner, R., Yildiz, O., Celik, I., Doganay, H. L., …Ozdarendeli, A... & TURKOVAC Study Group. (2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines, 10(11), 1865.

Taşlı, N. P., Gönen, Z. B., Kırbaş, O. K., Gökdemir, N. S., Bozkurt, B. T., Bayrakcı, B., … Yetiskin, H., Kaplan, B., Islam Pavel S.T. I.,... Ozdarendeli, A, Cetin, M. (2022). Preclinical studies on convalescent human immune plasma-derived exosome: Omics and antiviral properties to SARS-CoV-2. Frontiers in immunology, 13, 904.

Gül, F., GÖNEN, Z., Jones, O., Taşlı, N., ZARARSIZ, G., Ünal, E., Ozdarendeli, A... Uygut M.A…&Çetin, M. (2022). A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Frontiers in Immunology, 13.

Nurettin, C., Engin, B., Sukru, T., Munir, A., Zati, V., & Aykut, O. (2022). The Seroprevalence of Crimean-Congo Hemorrhagic Fever in Wild and Domestic Animals: An Epidemiological Update for Domestic Animals and First Seroevidence in Wild Animals from Turkiye. Veterinary Sciences, 9(9), 462.

Pavel, S. T. I., Yetiskin, H., Uygut, M. A., Aslan, A. F., Aydın, G., İnan, Ö., ... & Ozdarendeli, A. (2021). Development of an inactivated vaccine against SARS CoV-2. Vaccines, 9(11), 1266.

Berber, E., Çanakoğlu, N., Tonbak, Ş., & Ozdarendeli, A. (2021). Development of a protective inactivated vaccine against Crimean–Congo hemorrhagic fever infection. Heliyon, 7(10), e08161.

Karaaslan, E., Çetin, N. S., Kalkan-Yazıcı, M., Hasanoğlu, S., Karakeçili, F., Özdarendeli, A., ... & Doymaz, M. Z. (2021). Immune responses in multiple hosts to Nucleocapsid Protein (NP) of Crimean-Congo Hemorrhagic Fever Virus (CCHFV). PLoS Neglected Tropical Diseases, 15(12), e0009973.

Gülce-İz, S., Elaldı, N., Can, H., Şahar, E. A., Karakavuk, M., Gül, A., …Ozdarendeli, A...  & Döşkaya, M. (2021). Development of a novel recombinant ELISA for the detection of Crimean-Congo hemorrhagic fever virus IgG antibodies. Scientific reports, 11(1), 5936.

Mamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, I., Gulec, B., Mammadova, G., Ozdarendeli, A, Yetiskin, H., Kaplan, B., Islam Pavel S.T. I., Uygut M.A., Hasanova, G. (2021). Production and characterization of nucleocapsid and RBD cocktail antigens of SARS-CoV-2 in Nicotiana benthamiana plant as a vaccine candidate against COVID-19. Vaccines, 9(11), 1337.

Mamedov, T., Yuksel, D., Ilgın, M., Gurbuzaslan, I., Gulec, B., Yetiskin, H., Uygut M.A., Islam Pavel S.T. I.,Ozdarendeli A.. & Hasanova, G. (2021). Plant-produced glycosylated and in vivo deglycosylated receptor binding domain proteins of SARS-CoV-2 induce potent neutralizing responses in mice. Viruses, 13(8), 1595.

Pavel, S. T. I., Yetiskin, H., Aydin, G., Holyavkin, C., Uygut, M. A., Dursun, Z. B., ... & Ozdarendeli, A. (2020). Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PloS one, 15(9), e0238614.

Pavel, S. T. I., Yetiskin, H., Kalkan, A., & Ozdarendeli, A. (2020). Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model. PLoS Neglected Tropical Diseases, 14(11), e0008834.

Alm, E., Broberg, E. K., Connor, T., Hodcroft, E. B., Komissarov, A. B., Maurer-Stroh, S., ... & Pereyaslov, D. (2020). Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance, 25(32), 2001410.

Inci, A., Doganay, M., Özdarendeli, A., Düzlü, Ö., & Yıldırım, A. (2018). Overview of zoonotic diseases in Turkey: the one health concept and future threats, Turkiye Parazitolojii Derg. 42  39–80.

Canakoglu, N., Berber, E., Tonbak, S., Ertek, M., Sozdutmaz, I., Aktas, M., ... & Ozdarendeli, A. (2015). Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS neglected tropical diseases, 9(3), e0003579.

Canakoglu, N., Berber, E., Tonbak, S., Ertek, M., Sozdutmaz, I., Aktas, M., ... & Ozdarendeli, A. (2015). Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS neglected tropical diseases, 9(3), e0003579.titration of Crimean-Congo hemorrhagic fever virus. Journal of virological methods, 187(1), 26-31.

Canakoglu, N., Berber, E., Ertek, M., Yoruk, M. D., Tonbak, S., Bolat, Y., ... & Ozdarendeli, A. (2013). Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus. Virology journal, 10, 1-7.

Özdarendeli, A., Çanakoğlu, N., Berber, E., Aydın, K., Tonbak, Ş., Ertek, M., ... & Kalkan, A. (2010). The complete genome analysis of Crimean-Congo hemorrhagic fever virus isolated in Turkey. Virus research, 147(2), 288-293.

Ozdarendeli, A., Aydin, K, Tonbak, S., Aktas, M., Altay, K., Koksal, ... & Kalkan, A. (2008). Genetic analysis of the M RNA segment of Crimean-Congo hemorrhagic fever virus strains in Turkey. Archives of virology, 153, 37-44.

Tonbak, S., Aktas, M., Altay, K., Azkur, A. K., Kalkan, A., Bolat, Y., ... & Ozdarendeli, A. (2006). Crimean-Congo hemorrhagic fever virus: genetic analysis and tick survey in Turkey. Journal of clinical microbiology, 44(11), 4120-4124.